Toll‐like receptor 7/8‐matured RNA‐transduced dendritic cells as post‐remission therapy in acute myeloid leukaemia: results of a phase I trial
FS Lichtenegger, FM Schnorfeil… - Clinical & …, 2020 - Wiley Online Library
Objectives Innovative post‐remission therapies are needed to eliminate residual AML cells.
DC vaccination is a promising strategy to induce anti‐leukaemic immune responses …
DC vaccination is a promising strategy to induce anti‐leukaemic immune responses …
[HTML][HTML] Toll‐like receptor 7/8‐matured RNA‐transduced dendritic cells as post‐remission therapy in acute myeloid leukaemia: results of a phase I trial
FS Lichtenegger, FM Schnorfeil, M Rothe… - Clinical & …, 2020 - ncbi.nlm.nih.gov
Objectives Innovative post‐remission therapies are needed to eliminate residual AML cells.
DC vaccination is a promising strategy to induce anti‐leukaemic immune responses …
DC vaccination is a promising strategy to induce anti‐leukaemic immune responses …
Toll‐like receptor 7/8‐matured RNA‐transduced dendritic cells as post‐remission therapy in acute myeloid leukaemia: results of a phase I trial
FS Lichtenegger, FM Schnorfeil… - Clinical & …, 2020 - epub.ub.uni-muenchen.de
Objectives Innovative post‐remission therapies are needed to eliminate residual AML cells.
DC vaccination is a promising strategy to induce anti‐leukaemic immune responses …
DC vaccination is a promising strategy to induce anti‐leukaemic immune responses …
Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial
FS Lichtenegger, FM Schnorfeil… - Clinical & …, 2020 - pubmed.ncbi.nlm.nih.gov
Objectives Innovative post-remission therapies are needed to eliminate residual AML cells.
DC vaccination is a promising strategy to induce anti-leukaemic immune responses …
DC vaccination is a promising strategy to induce anti-leukaemic immune responses …
Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial.
FS Lichtenegger, FM Schnorfeil, M Rothe… - Clinical & …, 2020 - europepmc.org
Objectives Innovative post-remission therapies are needed to eliminate residual AML cells.
DC vaccination is a promising strategy to induce anti-leukaemic immune responses …
DC vaccination is a promising strategy to induce anti-leukaemic immune responses …
Toll‐like receptor 7/8‐matured RNA‐transduced dendritic cells as post‐remission therapy in acute myeloid leukaemia: results of a phase I trial.
FS Lichtenegger, FM Schnorfeil… - Clinical & …, 2020 - search.ebscohost.com
Objectives: Innovative post‐remission therapies are needed to eliminate residual AML cells.
DC vaccination is a promising strategy to induce anti‐leukaemic immune responses …
DC vaccination is a promising strategy to induce anti‐leukaemic immune responses …
Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial
FS Lichtenegger, FM Schnorfeil… - Clinical & …, 2020 - scholarlypublications …
Objectives Innovative post-remission therapies are needed to eliminate residual AML cells.
DC vaccination is a promising strategy to induce anti-leukaemic immune responses …
DC vaccination is a promising strategy to induce anti-leukaemic immune responses …
Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial.
FS Lichtenegger, FM Schnorfeil, M Rothe, K Deiser… - 2020 - mediatum.ub.tum.de
Objectives: Innovative post-remission therapies are needed to eliminate residual AML cells.
DC vaccination is a promising strategy to induce anti-leukaemic immune responses …
DC vaccination is a promising strategy to induce anti-leukaemic immune responses …
Toll‐like receptor 7/8‐matured RNA‐transduced dendritic cells as post‐remission therapy in acute myeloid leukaemia: results of a phase I trial
FS Lichtenegger, FM Schnorfeil… - Clinical & …, 2020 - search.proquest.com
Objectives Innovative post‐remission therapies are needed to eliminate residual AML cells.
DC vaccination is a promising strategy to induce anti‐leukaemic immune responses …
DC vaccination is a promising strategy to induce anti‐leukaemic immune responses …
Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial.
FS Lichtenegger, FM Schnorfeil, M Rothe… - Clinical & …, 2020 - europepmc.org
Objectives Innovative post-remission therapies are needed to eliminate residual AML cells.
DC vaccination is a promising strategy to induce anti-leukaemic immune responses …
DC vaccination is a promising strategy to induce anti-leukaemic immune responses …